Cancer chemotherapy and biological response modifiers annual 20 /
edited by G. Gianccone, R. Schilsky, P. Sondel
- 1st edition
- Amsterdam : Elsevier, c2002
- xvii, 803 p. : ill. ; 27 cm
Includes Bibliographical references and index
Contents Introduction I. Drugs 1. Thymidylates synthase inhibitors 2. New nucleoside analogue in clinical development 3. Anthracyclines 4. Tubulin-targeting agents 5. Topoisomerase I interactive agents 6. Topoisomerase II inhibitors 7. Farnesyltransferase inhibitors 8. Cyclin-depent kinases as targets for cancer therapy 9. DNA-binding agents 10. The evolving role of endocrine therapy for the treatment and prevention of breast cancer 11. New targets for cancer chemotherapy
II. Biological Response Modifiers 12. The graft-versus-turmor effect and escape of malignancy from immune regulation 13. Donor Lymphocyte infusions for hematopoietic malignancy 14. Diptheria toxin conjugate therapy of cancer 15. Genetical engineered T cells as Adoptive immunotherapy of cancer 16. Integrating IL-12 into therapeutic cancer vaccines 17. Immunotherapy for breast cancer 18. Immunotherapy of Melanoma 19. CEA loaded dendritic cell vaccines
III. Tumours 20. Lymphomas 21. Head and neck cancer 22. Cancers of the large bowel and hepatobiliary track 23. Malignant neuroendocrine tumors 24. Genitourinary Malignancies 25. Breast Cancer 26. Advances in the management of melanoma 27. Sarcomas 28. Brain Tumors 29. Biology and Therapy of Malignant solids tumors in childhood 30. Supportive Care 31. AIDS - associated malignancies
IV. Special Section - Lung Cancer 32. CT. screening for Lung Cnacer 33. Combined modality treatment of Lung cancer(NSCLC and SCLC) 34. Update on the systemic treatment of lung cancer 35. New targets for the treatment of advanced non-small cell lung cancer 36. Novel Therapies for the treatment of non-small cell lung cancer